首页> 外文OA文献 >Nucleosomes in pancreatic cancer patients during radiochemotherapy
【2h】

Nucleosomes in pancreatic cancer patients during radiochemotherapy

机译:在放化疗期间胰腺癌患者的核

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nucleosomes appear spontaneously in elevated concentrations in the serum of patients with malignant diseases as well as during chemo- and radiotherapy. We analyzed whether their kinetics show typical characteristics during radiochemotherapy and enable an early estimation of therapy efficacy. We used the Cell Death Detection Elisaplus ( Roche Diagnostics) and investigated the course of nucleosomes in the serum of 32 patients with a local stage of pancreatic cancer who were treated with radiochemotherapy for several weeks. Ten of them received postsurgical therapy, 21 received primary therapy and 1 received therapy for local relapse. Blood was taken before the beginning of therapy, daily during the first week, once weekly during the following weeks and at the end of radiochemotherapy. The response to therapy was defined according to the kinetics of CA 19-9: a decrease of CA 19-9 650% after radiochemotherapy was considered as `remission'; an increase of >= 100% ( which was confirmed by two following values) was defined as `progression'. Patients with `stable disease' ranged intermediately. Most of the examined patients showed a decrease of the concentration of nucleosomes within 6 h after the first dose of radiation. Afterwards, nucleosome levels increased rapidly, reaching their maximum during the following days. Patients receiving postsurgery, primary or relapse therapies did not show significant differences in nucleosome values during the time of treatment. Single nucleosome values, measured at 6, 24 and 48 h after the application of therapy, could not discriminate significantly between patients with no progression and those with progression of disease. However, the area under the curve of the first 3 days, which integrated all variables of the initial therapeutic phase, showed a significant correlation with the progression-free interval ( p = 0.008). Our results indicate that the area under the curve of nucleosomes during the initial phase of radiochemotherapy could be valuable for the early prediction of the progression-free interval. Copyright (C) 2005 S. Karger AG, Basel.
机译:在恶性疾病患者的血清中以及化学疗法和放射疗法期间,核小体以升高的浓度自发出现。我们分析了它们的动力学在放化疗过程中是否表现出典型特征,并能够早期评估治疗效果。我们使用细胞死亡检测Elisaplus(罗氏诊断公司(Roche Diagnostics)),研究了32例局部胰腺癌患者的血清中核小体的病程,这些患者接受了放化疗治疗了几周。其中有10人接受了术后治疗,有21人接受了初级治疗,还有1人接受了局部复发治疗。在治疗开始之前,在第一周的每天,在接下来的几周的每周一次以及在放化疗结束时,每周采一次血。根据CA 19-9的动力学定义对治疗的反应:放化疗后CA 19-9 650%的降低被认为是“缓解”;将> = 100%的增加(由以下两个值确认)定义为“进度”。患有“稳定疾病”的患者介于中等水平。接受检查的大多数患者在首次辐射后6小时内显示出核小体浓度的降低。此后,核小体水平迅速增加,并在接下来的几天达到最大值。接受手术后,初次或复发治疗的患者在治疗期间的核小体值无明显差异。在应用治疗后的6、24和48小时测得的单个核小体值,在没有进展的患者和有疾病进展的患者之间没有明显的区别。但是,整合了初始治疗阶段所有变量的前三天曲线下面积显示了与无进展间隔的显着相关性(p = 0.008)。我们的结果表明,放射化学疗法初始阶段核小体曲线下的面积对于无进展间隔的早期预测可能有价值。版权所有(C)2005 S.Karger AG,巴塞尔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号